Global and Japan Cefotaxime Sodium API Market Insights, Forecast to 2027

Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.
Market competition is intense. REYOUNG, Nectar Lifesciences, Medya Pharma, Sandoz, Kelun, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accountted for 57.98% market share in 2019.

Market Analysis and Insights: Global and Japan Cefotaxime Sodium API Market
This report focuses on global and Japan Cefotaxime Sodium API market.
In 2020, the global Cefotaxime Sodium API market size was US$ 102.1 million and it is expected to reach US$ 96.4 million by the end of 2027, with a CAGR of -0.8% during 2021-2027. In Japan the Cefotaxime Sodium API market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Cefotaxime Sodium API Scope and Market Size
Cefotaxime Sodium API market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Cefotaxime Sodium API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Cefotaxime Sodium API market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
ChP
USP
EP

Segment by Application
Single Injection
Compound Injection

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
REYOUNG
Nectar Lifesciences
Medya Pharma
Sandoz
Kelun
NCPC
Aurobindo Pharma
United Laboratories
Orchid Pharma
CSPC
Kopran
Covalent
ACS Dobfar
Dawnrays
Sterile India